Once you start taking ibrutinib/Eco, can you stop taking it at will?

Ibrutinib (Ibrutinib), as an oral BTK inhibitor, plays an important role in the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and Waldenstrom's macroglobulinemia (WM). Patients often worry about a core issue, which is whether once they start taking ibrutinib, it means they cannot stop it at will. In fact, ibrutinib treatment regimens are often long-term or even continuous, which is closely related to its mechanism of action and the characteristics of the disease itself.

Ibrutinib blocks the signaling of malignant B cells by irreversibly binding to BTK (Bruton tyrosine kinase), thereby inhibiting the proliferation and survival of tumor cells. However, this effect is not permanent once and for all. If the patient stops taking the drug at will without medical guidance, the remaining malignant cells may become active again, leading to disease progression or even recurrence. In particular, diseases such as CLL and MCL are characterized by chronic progression and easy relapse, and arbitrary discontinuation of treatment may increase the risk of drug resistance and make subsequent treatment more complicated.

Clinical experience shows that some patients choose to interrupt treatment due to drug side effects or financial burden, but usually the dose is adjusted, the drug is temporarily stopped, or the regimen is changed under the doctor's evaluation, rather than unilaterally stopping at will. The treatment concept of ibrutinib is different from traditional chemotherapy. It is more like a long-term targeted management tool rather than a short-term shock therapy.

In addition, tolerance varies widely among patients, and some may need to reduce their dose to continue to benefit rather than discontinuing the drug entirely. Research also suggests that in some cases, short-term discontinuation of medication may not cause an immediate rebound of the disease, but long-term arbitrary discontinuation carries a greater risk. Especially when it is covered by domestic medical insurance, patients should pay more attention to how to manage it under the guidance of a doctor rather than stopping the medication on their own.

Reference materials:https://www.imbruvica.com/